medRxiv PreprintsInternational15 November 2026
Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
ABSTRACT Introduction: Clinicians and Medicaid programs must decide whether to continue prescription stimulants in pregnancies complicated by opioid use disorder (OUD), yet no safety evidence exists for this population and stimulant coverage is frequently restricted. We evaluated maternal and neonatal outcomes associated with prescription stimulant treatment during pregnancy among individuals with OUD, including those with co-occurring stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD). Methods: We conducted a retrospective cohort study of Medicaid-insured pregna
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.